Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study.
The efficacy, tolerability and side effects of a 3-day treatment for acute urinary infection in general practice with norfloxacin (400 mg 12 hourly) or nalidixic acid/citrate (1 sachet 8 hourly) were compared in a randomized study. Patient groups had similar demography, symptomatology and initial infecting bacteria. Of the evaluable 55 patients in each treatment group with initial bacteriuria, 53 (96%) had no bacteriuria at immediate follow-up after treatment with norfloxacin and 45 (82%) with nalidixic acid/citrate. The corresponding rates at late follow-up were 40/45 (89%) and 29/43 (67%) (P less than 0.05). Among the bacteriuric patients a significantly greater proportion were recorded as having cured and improved symptoms. The tolerability of norfloxacin seemed to be better than that of nalidixic acid/citrate.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000627:therapeutic use*; D002951:Citrates / Q000008:administration & dosage / Q000627:therapeutic use; D019343:Citric Acid; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D009643:Norfloxacin; D011897:Random Allocation; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000892:Anti-Infective Agents, Urinary; D002951:Citrates; D019343:Citric Acid; D009268:Nalidixic Acid; D009643:Norfloxacin